Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy-Reference-Cited by-同舟云学术

Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy

Published:2012-09-15 Issue:2 Volume:202 Page:117-124
ISSN:0300-8584
Container-title:Medical Microbiology and Immunology
language:en
Short-container-title:Med Microbiol Immunol

Author:

Stephan Christoph,Bartha Valentin,Herrmann Eva,von Hentig Nils,Khaykin Pavel,Knecht Gaby,Gute Peter,Brodt Hans-Reinhard,Stürmer Martin,Berger Annemarie,Bickel Markus

Publisher

Springer Science and Business Media LLC

Subject

Microbiology (medical),Immunology,General Medicine,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00430-012-0276-8.pdf

Reference17 articles.

1. Stephan C, von Hentig N, Kourbeti I, Dauer B, Mösch M, Lutz T, Klauke S, Harder S, Kurowski M, Staszewski S (2004) Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 18:503–508

2. Staszewski S, Babacan E, Stephan C, Haberl A, Carlebach A, Gute P, Klauke S, Hermschulte Y, Stuermer M, Dauer B, Frankfurt HIV Cohort (2006) The LOPSAQ Study: 48-Week Analysis Of A Boosted Double Protease Inhibitor Regimen Containing Lopinavir/Ritonavir Plus Saquinavir Without Additional Antiretroviral Therapy. J Antimicrob Chemother 58:1024–1030

3. Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, Katlama C, Pialoux G, Jacomet C, Piketty C, Bollens D, Molina JM, Chêne G, ANRS 139 TRIO Trial Group (2009) High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 49:1441–1449

4. Imaz A, del Saz SV, Ribas MA, Curran A, Caballero E, Falcó V, Crespo M, Ocaña I, Diaz M, de Gopegui ER, Riera M, Ribera E (2009) Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 52:382–386

5. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW, AIDS Clinical Trials Group Study A5142 Team (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358:2095–2106

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy;Medical Microbiology and Immunology;2016-07-28

2. Improved virological and immunological efficacy of resistance-guided switch in antiretroviral therapy: a Frankfurt HIV cohort analysis;Medical Microbiology and Immunology;2014-08-23

3. Vaccination against infectious diseases: What is promising?;Medical Microbiology and Immunology;2014-07-27